GlassScriptPhysician profile
Ravikumar R Peddireddy
NPI 1710989546
$1,712.76
in general payments reported to CMS, 2019-2025
27 companies · $60.74 in 2025
The $60.74 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $157 · 2021: $589 · 2022: $252 · 2023: $119 · 2024: $199 · 2025: $60.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $362.23 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $394.00 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $227.01 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $134.20 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $128.81 | 2021 | |
| Novartis Pharmaceuticals Corporation | $123.76 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.51 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $64.50 | 2020-2022 | |
| Eisai INC. | $63.60 | 2021-2022 | |
| Exact Sciences Corporation | $49.19 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biogen, INC. | $48.48 | 2020-2021 | |
| Abbvie INC. | $46.95 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $43.62 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $39.28 | 2019-2022 | |
| Pfizer INC. | $32.28 | 2022-2023 | |
| Lilly USA, LLC | $28.99 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.47 | 2021 | |
| Genentech USA, INC. | $24.26 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $20.63 | 2024 | Camzyos |
| Sanofi Pasteur INC. | $18.72 | 2021 | |
| Amarin Pharma, INC. | $17.95 | 2020 | |
| Phathom Pharmaceuticals, INC. | $17.63 | 2024 | Voquezna |
| Ibsa Pharma INC. | $16.60 | 2021 | |
| Shield Therapeutics INC | $15.65 | 2024 | |
| Horizon Therapeutics Plc | $15.31 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.26 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.23 | 2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravikumar Peddireddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.